Optimizing Sustained Release Drug Formulation, Showcasing Advancements in Suprachoroidal Delivery, and Assessing Clinical Benefits to Demonstrate Safe, Efficacious and Long-Lasting Delivery to the Eye
Translating Long Lasting Efficacy & Less Invasive Retinal Drug Delivery
The importance of matching the right drug delivery route to the right ophthalmic disease is more pressing than ever. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss and explore innovations and future directions for ophthalmic device and formulation development. Delve into the latest in-depth analysis of intravitreal, subretinal, suprachoroidal and topical delivery and explore advancements in ophthalmic pharmacology.
Captalizing on a new wave of pipeline momentum seen with the reapproval of Roche/Genentech’s Susvimo, AbbVie’s recent implant partnership with Ripple, and suprachoroidal delivery revolutionizing gene therapy, this summit unites 60+ clinical and preclinical ocular experts, ophthalmic device engineers, product development leaders and formulation specialists from the likes of Genentech, Bayer, Regeneron, AbbVie, Clearside, REGENXBIO, Ocular and more as they address solutions to achieve minimally invasive delivery and sustained drug release for ophthalmology.
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Hear Why Your Industry Peers Attended:
"Size of the meeting allowed meaningful interactions with all guests. Scientific talks were specific to the topic and delved into more detail when compared to similar talks at more generic conferences"
Senior Scientist, GelMEDIX
"The topics presented had a good balance of breadth and depth. The format allowed a great amount of interaction from the audience. I learned a tremendous amount from my fellow participants in the audience during each presentation’’
Chief Scientific Officer, Oxular
"This conference brings together industry experts in the field of ocular drug design and delivery. They will share their valuable experience in drug development that will likely help guide your own work"
Vice President, EyePoint Pharmaceuticals
Other Events in the Ophthalmology & Sensory Series:
